Stay updated on PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.

Latest updates to the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page
- CheckyesterdayChange DetectedThe page’s footer revision indicator was updated from v3.5.0 to v3.5.3. This reflects a change to the site’s versioning rather than any updates to the clinical trial record itself.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 in the record history.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded revision v3.4.3 and removed revision v3.4.2 in the record history.SummaryDifference0.1%

- Check73 days agoChange DetectedA minor update to the record history shows a new revision v3.4.2 added and v3.4.1 removed, with no substantive study content affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check80 days agoChange DetectedThe Record History shows a new revision (v3.4.1) added and the previous revision (v3.4.0) removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check87 days agoChange DetectedThe new version adds a glossary toggle and color-coded change highlights (green for additions, red for deletions) with an updated revision notice (v3.4.0). The old revision note (v3.3.4) and the 'No FEAR Act Data' text were removed.SummaryDifference1%

Stay in the know with updates to PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.